EA201690069A1 - Применение высоких доз придопидина для лечения болезни хантингтона - Google Patents

Применение высоких доз придопидина для лечения болезни хантингтона

Info

Publication number
EA201690069A1
EA201690069A1 EA201690069A EA201690069A EA201690069A1 EA 201690069 A1 EA201690069 A1 EA 201690069A1 EA 201690069 A EA201690069 A EA 201690069A EA 201690069 A EA201690069 A EA 201690069A EA 201690069 A1 EA201690069 A1 EA 201690069A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
hantington
treatment
high dose
patient
Prior art date
Application number
EA201690069A
Other languages
English (en)
Inventor
Мерав Бассан
Эли Эял
Эстер Люкасевич Хагай
Анна Кристина Свеинсдоттер Теиге Виккенберг
Original Assignee
Тева Фармасьютикалз Интернэшнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фармасьютикалз Интернэшнл Гмбх filed Critical Тева Фармасьютикалз Интернэшнл Гмбх
Publication of EA201690069A1 publication Critical patent/EA201690069A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Способ лечения пациента-человека, пораженного болезнью Хантингтона, включающий в себя периодическое пероральное введение пациенту фармацевтической композиции, содержащей придопидин или его фармацевтически приемлемую соль, где пациенту ежедневно вводят более 90 мг придопидина.
EA201690069A 2013-06-21 2014-06-19 Применение высоких доз придопидина для лечения болезни хантингтона EA201690069A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13
PCT/US2014/043204 WO2014205229A1 (en) 2013-06-21 2014-06-19 Use of high dose pridopidine for treating huntington's disease

Publications (1)

Publication Number Publication Date
EA201690069A1 true EA201690069A1 (ru) 2016-06-30

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690069A EA201690069A1 (ru) 2013-06-21 2014-06-19 Применение высоких доз придопидина для лечения болезни хантингтона

Country Status (24)

Country Link
US (1) US10322119B2 (ru)
EP (1) EP3010506B1 (ru)
JP (1) JP2016523862A (ru)
KR (1) KR102316933B1 (ru)
CN (1) CN105592848A (ru)
AU (1) AU2014281414A1 (ru)
BR (1) BR112015029918A2 (ru)
CA (1) CA2913781C (ru)
CL (1) CL2015003690A1 (ru)
DK (1) DK3010506T3 (ru)
EA (1) EA201690069A1 (ru)
ES (1) ES2879631T3 (ru)
HK (1) HK1221646A1 (ru)
HU (1) HUE054783T2 (ru)
IL (1) IL242804B (ru)
MX (1) MX2015017307A (ru)
PE (2) PE20170302A1 (ru)
PH (1) PH12015502691A1 (ru)
PL (1) PL3010506T3 (ru)
SG (1) SG11201509729YA (ru)
TW (1) TW201529069A (ru)
UA (1) UA122999C2 (ru)
UY (1) UY35624A (ru)
WO (1) WO2014205229A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
KR102479759B1 (ko) * 2014-01-22 2022-12-21 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘의 변형된 방출 제제
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
WO2017015615A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
JP7278210B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
AU2017315783C1 (en) * 2016-08-24 2020-12-24 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating a subject with early stage huntington disease
AU2017326436A1 (en) * 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
PL3512506T3 (pl) 2016-09-16 2022-05-30 Prilenia Neurotherapeutics Ltd. Zastosowanie pridopidyny w leczeniu zespołu retta
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
EP4154882A1 (en) 2017-08-14 2023-03-29 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
BR112020004045A2 (pt) * 2017-08-30 2020-09-01 Prilenia Neurotherapeutics Ltd. formas de dosagem de elevada concentração de pridopidina
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
CN114727761A (zh) * 2019-09-17 2022-07-08 豪夫迈·罗氏有限公司 患有运动障碍的患者的个性化保健的改善
US20230390232A1 (en) * 2020-10-28 2023-12-07 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
NZ580856A (en) 2007-04-12 2011-11-25 Nsab Af Neurosearch Sweden Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
CN104768545A (zh) 2012-09-27 2015-07-08 泰华制药工业有限公司 雷沙吉兰和普多比啶组合以治疗神经退化性病症,尤其亨廷顿氏病
IN2015DN03219A (ru) 2012-09-27 2015-10-02 Teva Pharma
KR102479759B1 (ko) 2014-01-22 2022-12-21 프리레니아 뉴로테라퓨틱스 엘티디. 프리도피딘의 변형된 방출 제제
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
JP7278210B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
AU2017315783C1 (en) 2016-08-24 2020-12-24 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating a subject with early stage huntington disease
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
PL3512506T3 (pl) 2016-09-16 2022-05-30 Prilenia Neurotherapeutics Ltd. Zastosowanie pridopidyny w leczeniu zespołu retta

Also Published As

Publication number Publication date
EP3010506A4 (en) 2017-02-08
PE20170302A1 (es) 2017-03-31
BR112015029918A2 (pt) 2017-07-25
EP3010506B1 (en) 2021-05-12
SG11201509729YA (en) 2015-12-30
MX2015017307A (es) 2016-08-03
EP3010506A1 (en) 2016-04-27
UY35624A (es) 2015-01-30
AU2014281414A1 (en) 2016-01-21
HUE054783T2 (hu) 2021-09-28
WO2014205229A8 (en) 2015-04-09
ES2879631T3 (es) 2021-11-22
PE20160195A1 (es) 2016-05-14
JP2016523862A (ja) 2016-08-12
DK3010506T3 (da) 2021-07-12
WO2014205229A1 (en) 2014-12-24
CN105592848A (zh) 2016-05-18
CA2913781A1 (en) 2014-12-24
US20140378508A1 (en) 2014-12-25
TW201529069A (zh) 2015-08-01
IL242804B (en) 2022-02-01
PH12015502691A1 (en) 2016-03-14
KR20160055122A (ko) 2016-05-17
US10322119B2 (en) 2019-06-18
CL2015003690A1 (es) 2016-10-28
PL3010506T3 (pl) 2021-11-02
UA122999C2 (uk) 2021-02-03
KR102316933B1 (ko) 2021-10-26
CA2913781C (en) 2022-05-10
HK1221646A1 (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
BR112015028581A2 (pt) composição farmacêutica de dosagem baixa, utilização do ácido, método para o tratamento da doença inflamatória e composição farmacêutica
NZ713490A (en) Oral suspension for treating eosinophilic esophagitis
UA83971U (ru) Способ лечения гипертонической болезни
AR096674A1 (es) Método de tratamiento de un paciente humano que sufre de la enfermedad de huntington